Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: A prospective cross-over drug–drug interaction study
- 1 April 2011
- journal article
- clinical trial
- Published by Elsevier in European Journal of Cancer
- Vol. 47 (6) , 831-838
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Validated assay for studying activity profiles of human liver UGTs after drug exposure: inhibition and induction studiesAnalytical and Bioanalytical Chemistry, 2010
- Distinct Effects of Omeprazole and Rabeprazole on the Tacrolimus Blood Concentration in a Kidney Transplant RecipientDrug Metabolism and Pharmacokinetics, 2007
- Interaction between Tacrolimus and Omeprazole in a Pediatric Liver Transplant RecipientTransplantation, 2006
- Drug interactions in oncologyThe Lancet Oncology, 2004
- Regulation of CYP3A4 Expression in Human Hepatocytes by Pharmaceuticals and Natural ProductsDrug Metabolism and Disposition, 2003
- Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43European Journal of Pharmacology, 2003
- Proton pump inhibitors and their drug interactions: an evidence-based approachEuropean Journal of Gastroenterology & Hepatology, 2001
- Lansoprazole and omeprazole in the treatment of acid peptic disordersAmerican Journal of Health-System Pharmacy, 1996
- Comparative effects of omeprazole on xenobiotic metabolizing enzymes in the rat and human*Clinical Pharmacology & Therapeutics, 1995
- OMEPRAZOLE INHIBITS ELIMINATION OF DIAZEPAMThe Lancet, 1984